STOCK TITAN

[8-K] Alkermes plc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Alkermes plc furnished an update on its business, announcing financial results for the three and nine months ended September 30, 2025 and updating financial expectations for the year ending December 31, 2025.

The company made its press release and the investor presentation available as Exhibits 99.1 and 99.2, respectively, in connection with its conference call on October 28, 2025. The materials are furnished, not filed, under the Exchange Act.

Alkermes plc ha fornito un aggiornamento sulla sua attività, annunciando i risultati finanziari per i tre e nove mesi conclusi il 30 settembre 2025 e aggiornando le previsioni finanziarie per l'anno che termina il 31 dicembre 2025.

La società ha reso disponibili il comunicato stampa e la presentazione agli investitori come Allegati 99.1 e 99.2, rispettivamente, in relazione alla sua conference call del 28 ottobre 2025. I materiali sono forniti, non depositati, conformemente al Securities Exchange Act.

Alkermes plc presentó una actualización de su negocio, anunciando los resultados financieros de los tres y nueve meses terminados al 30 de septiembre de 2025 y actualizando las expectativas financieras para el año que termina el 31 de diciembre de 2025.

La empresa hizo público su comunicado de prensa y la presentación para inversores disponibles como Exhibits 99.1 y 99.2, respectivamente, en relación con su conferencia telefónica del 28 de octubre de 2025. Los materiales se proporcionan, no se presentan ante la Exchange Act.

Alkermes plc는 2025년 9월 30일 종료된 3개월 및 9개월의 재무실적을 발표하고 2025년 12월 31일에 종료되는 연간 재무 전망을 업데이트했습니다.

회사는 보도자료와 투자자 프레젠테이션을 각각 Exhibit 99.1 및 99.2로 2025년 10월 28일의 컨퍼런스 콜과 관련하여 공개했습니다. 자료는 Exchange Act에 따라 제출된 것이 아니라 furnished로 제공됩니다.

Alkermes plc a publié une mise à jour de ses activités, annonçant les résultats financiers pour les trois et neuf mois clos le 30 septembre 2025 et actualisant les prévisions financières pour l'année se terminant le 31 décembre 2025.

La société a rendu son communiqué de presse et sa présentation destinées aux investisseurs disponibles en tant que pièces 99.1 et 99.2, respectivement, dans le cadre de son appel-conférence du 28 octobre 2025. Les documents sont fournis, et non déposés, en vertu du Exchange Act.

Alkermes plc hat ein Update zu seinem Geschäft vorgelegt und die finanziellen Ergebnisse für die drei und neun Monate zum 30. September 2025 bekannt gegeben sowie die finanziellen Erwartungen für das Jahr bis zum 31. Dezember 2025 aktualisiert.

Das Unternehmen machte seine Pressemitteilung und die Investor-Präsentation als Exhibits 99.1 bzw. 99.2 im Zusammenhang mit seiner Telefonkonferenz am 28. Oktober 2025 verfügbar. Die Materialien werden bereitgestellt, nicht eingereicht, gemäß dem Exchange Act.

Alkermes plc قدمت تحديثاً عن أعمالها، معلنة نتائجها المالية للفترة من ثلاثة وتسعة أشهر المنتهية في 30 سبتمبر 2025 وتحديث التوقعات المالية للسنة المنتهية في 31 ديسمبر 2025.

قامت الشركة بإتاحة بيانها الصحفي وعرض المستثمرين كالمرفقين 99.1 و99.2، على التوالي، فيما يتعلق بمكالمة المؤتمر الخاصة بها في 28 أكتوبر 2025. المواد منشورة، وليست مقدمة وفقاً لقانون التداول Exchange Act.

Positive
  • None.
Negative
  • None.

Alkermes plc ha fornito un aggiornamento sulla sua attività, annunciando i risultati finanziari per i tre e nove mesi conclusi il 30 settembre 2025 e aggiornando le previsioni finanziarie per l'anno che termina il 31 dicembre 2025.

La società ha reso disponibili il comunicato stampa e la presentazione agli investitori come Allegati 99.1 e 99.2, rispettivamente, in relazione alla sua conference call del 28 ottobre 2025. I materiali sono forniti, non depositati, conformemente al Securities Exchange Act.

Alkermes plc presentó una actualización de su negocio, anunciando los resultados financieros de los tres y nueve meses terminados al 30 de septiembre de 2025 y actualizando las expectativas financieras para el año que termina el 31 de diciembre de 2025.

La empresa hizo público su comunicado de prensa y la presentación para inversores disponibles como Exhibits 99.1 y 99.2, respectivamente, en relación con su conferencia telefónica del 28 de octubre de 2025. Los materiales se proporcionan, no se presentan ante la Exchange Act.

Alkermes plc는 2025년 9월 30일 종료된 3개월 및 9개월의 재무실적을 발표하고 2025년 12월 31일에 종료되는 연간 재무 전망을 업데이트했습니다.

회사는 보도자료와 투자자 프레젠테이션을 각각 Exhibit 99.1 및 99.2로 2025년 10월 28일의 컨퍼런스 콜과 관련하여 공개했습니다. 자료는 Exchange Act에 따라 제출된 것이 아니라 furnished로 제공됩니다.

Alkermes plc a publié une mise à jour de ses activités, annonçant les résultats financiers pour les trois et neuf mois clos le 30 septembre 2025 et actualisant les prévisions financières pour l'année se terminant le 31 décembre 2025.

La société a rendu son communiqué de presse et sa présentation destinées aux investisseurs disponibles en tant que pièces 99.1 et 99.2, respectivement, dans le cadre de son appel-conférence du 28 octobre 2025. Les documents sont fournis, et non déposés, en vertu du Exchange Act.

Alkermes plc hat ein Update zu seinem Geschäft vorgelegt und die finanziellen Ergebnisse für die drei und neun Monate zum 30. September 2025 bekannt gegeben sowie die finanziellen Erwartungen für das Jahr bis zum 31. Dezember 2025 aktualisiert.

Das Unternehmen machte seine Pressemitteilung und die Investor-Präsentation als Exhibits 99.1 bzw. 99.2 im Zusammenhang mit seiner Telefonkonferenz am 28. Oktober 2025 verfügbar. Die Materialien werden bereitgestellt, nicht eingereicht, gemäß dem Exchange Act.

Alkermes plc قدمت تحديثاً عن أعمالها، معلنة نتائجها المالية للفترة من ثلاثة وتسعة أشهر المنتهية في 30 سبتمبر 2025 وتحديث التوقعات المالية للسنة المنتهية في 31 ديسمبر 2025.

قامت الشركة بإتاحة بيانها الصحفي وعرض المستثمرين كالمرفقين 99.1 و99.2، على التوالي، فيما يتعلق بمكالمة المؤتمر الخاصة بها في 28 أكتوبر 2025. المواد منشورة، وليست مقدمة وفقاً لقانون التداول Exchange Act.

Alkermes plc 已就其业务更新,宣布截至2025年9月30日的三个月和九个月财务业绩,并更新截至2025年12月31日年度的财务预期。

公司已将新闻稿及投资者介绍材料分别以 Exhibits 99.1 和 99.2 的形式公开,供其于2025年10月28日电话会议使用。这些材料是按照美国证券交易法(Exchange Act)提供的,而非备案。

False0001520262Alkermes plc.00015202622025-10-282025-10-28

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 28, 2025

ALKERMES PUBLIC LIMITED COMPANY

(Exact name of registrant as specified in its charter)

 

Ireland

 

001-35299

 

98-1007018

(State or other jurisdiction

 

(Commission

 

(IRS Employer

of incorporation)

 

File Number)

 

Identification No.)

 

 

 

 

 

 

Connaught House, 1 Burlington Road

Dublin 4, Ireland D04 C5Y6

(Address of principal executive offices)

 

Registrant's telephone number, including area code: + 353-1-772-8000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Ordinary shares, $0.01 par value

 

ALKS

 

Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 


 

Item 2.02 Results of Operations and Financial Condition.

 

On October 28, 2025, Alkermes plc (the “Company”) announced financial results for the three and nine months ended September 30, 2025 and updated financial expectations for the year ending December 31, 2025. Copies of the related press release and the investor presentation to be displayed during the Company’s conference call on October 28, 2025 discussing such financial results and updated financial expectations are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively. This information, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

EXHIBIT INDEX

 

Exhibit No.

 

Description

99.1

 

Press release issued by Alkermes plc on October 28, 2025 announcing financial results for the three and nine months ended September 30, 2025 and updating financial expectations for the year ending December 31, 2025.

99.2

 

Investor presentation to be displayed by Alkermes plc on October 28, 2025.

104

 

Cover page interactive data file (embedded within the Inline XBRL document).

 

2


 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

ALKERMES PLC

 

 

Date: October 28, 2025

By:

 

/s/ Joshua Reed

 

 

 

Joshua Reed

 

 

 

Senior Vice President, Chief Financial Officer (Principal Financial Officer)

 

3


Alkermes Plc

NASDAQ:ALKS

ALKS Rankings

ALKS Latest News

ALKS Latest SEC Filings

ALKS Stock Data

5.09B
161.38M
1.49%
104.97%
8.06%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
Ireland
DUBLIN 4